Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Trevi Therapeutics, a clinical-stage biopharmaceutical company listed on Nasdaq (TRVI), announced acceptance of two abstracts for presentations at the ERS Congress 2026 in Barcelona. The presentations focus on quality-of-life outcomes from their Phase 2b CORAL and Phase 2a RIVER trials evaluating their investigational therapy, oral nalbuphine exten…